 
Template version: May 28, 2014   
Title:  Celecoxib for Pain Management after Tonsillectomy  
Short Title  Celecoxib after Tonsillectomy  
Drug Name : [CONTACT_356185]  N/A 
eIRB Number  15-011707 
Protocol Date:   May 12, 2015 
Amendment 1 Date:  May 23, 2016              Amendment 3 Date: August 29, 2016  
Amendment 2 Date:            June 8, 2016 Amendment 4 Date:  October 31, 2016 
Amendment 5 Date: October [ADDRESS_443543] Floor, Wood Center  
The Children’s Hospi[INVESTIGATOR_6684]  
[ADDRESS_443544].  
Philadelphia, PA [ZIP_CODE]  
 
Phone 215- 590-3440  
email: [EMAIL_6856]  
 
 
 
    
   
   ii 
TABLE OF CONTENTS 
Table of Contents  ................................................................................................................... ii 
Abbreviations and Definitions of Te rms .............................................................................. v 
Abstract  ................................................................................................................................. vi 
Protocol Synopsis  ................................................................................................................. vii 
Table 1: Schedule of Study Procedures  .............................................................................. xi 
[ADDRESS_443545] OR INTERVENTION  ................................ ..... 1 
1.3 FINDINGS FROM CLINICAL STUDIES  ................................ ................................ ................................ ..... 1 
1.3.1  Clinical Studies  ................................ ................................ ................................ ...............................  1 
1.4 SELECTION OF DRUGS AND DOSAGES  ................................ ................................ ................................ ... 5 
1.5 RELEVANT LITERATURE AND DATA ................................ ................................ ................................ ..... 5 
1.6 COMPLIANCE STATEMENT  ................................ ................................ ................................ ....................  9 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ..............................  9 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ............................  9 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ .....................  9 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ..................  10 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ................................ ................................ ...............................  10 
3.1.1  Screening Phase  ................................ ................................ ................................ ............................  10 
3.1.2  Study Treatment Phase (Postop day 0 until pain- free, maximum 10 days)  ................................ ... 10 
3.1.3  Follow- up Pha se (Discontinuation of study drug to Postop day 30)  ................................ ............  12 
3.2 ALLOCATION TO TREATMENT GROUPS AND BLINDING  ................................ ................................ ...... 12 
3.3 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES ................................ ................................ . 13 
3.3.1  Duration of Study Participation  ................................ ................................ ................................ .... 13 
3.3.2  Total Number of Study Sites/Total Number of Subjects Projected ................................ ................  13 
3.4 STUDY POPULATION  ................................ ................................ ................................ ...........................  13 
3.4.1  Inclusion Criteria  ................................ ................................ ................................ ..........................  13 
3.4.2  Exclusion Criteria  ................................ ................................ ................................ .........................  14 
4 STUDY PROCEDURES  ................................ ................................ ................................ ..........................  15 
4.1 PRE-OP PHASE  ................................ ................................ ................................ ................................ .... 15 
4.2 STUDY TREATMENT PHASE (POSTOP DAY 0 UNTIL PAIN -FREE , MAXIMUM 10 DAYS ) ..........................  15 
4.2.1  Day of Surgery (Day 0)  ................................ ................................ ................................ .................  15 
4.2.2  Telephone Call 1 (Day 3 +/ - 1) ................................ ................................ ................................ ..... 15 
4.3 FOLLO W-UP PHASE (DISCONTINUATION OF ST UDY DRUG TO POSTOP DAY 30) ................................ ... 16 
4.3.1  Telephone Call 2 (Day 14 +/ - 1) ................................ ................................ ................................ ... 16 
4.3.2  Telephone Call 3 (Day 30 +/ - 2) ................................ ................................ ................................ ... [ADDRESS_443546] COMPLETION /WITHDRAWAL  ................................ ................................ ...............................  [ADDRESS_443547] Review  ................................ ................................ ................................ .................  18 
4.8.2  Laboratory Evaluations ................................ ................................ ................................ .................  19 
4.9 EFFICACY EVALUATIONS  ................................ ................................ ................................ ...................  19 
    
   
   iii 
4.9.1  Days receiving narcotic medication  ................................ ................................ ..............................  19 
4.9.2  Pain Scales (See Appendix)  ................................ ................................ ................................ ...........  19 
4.9.3  Measurement of Oxycodone and Acetaminophen Usage  ................................ ..............................  19 
4.9.4  Return to Normal Diet Assessment  ................................ ................................ ................................  20 
4.9.5  Data Collection from Hospi[INVESTIGATOR_91706]  ................................ ................................ ...............  20 
4.10 SAFETY EVALUATION  ................................ ................................ ................................ .........................  20 
5 STATISTICAL CONSIDER ATIONS  ................................ ................................ ................................ .... 21 
5.1 PRIMARY ENDPOINT  ................................ ................................ ................................ ...........................  21 
5.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ....................  21 
5.3 STATISTICAL METHODS  ................................ ................................ ................................ ......................  21 
5.3.1  Baseline Data  ................................ ................................ ................................ ................................  21 
5.3.2  Efficacy Analysis  ................................ ................................ ................................ ...........................  21 
5.3.3  Safety Analysis  ................................ ................................ ................................ ..............................  22 
5.4 SAMPLE SIZE AND POWER  ................................ ................................ ................................ ..................  22 
5.5 INTERIM SAFETY ANALYSIS  ................................ ................................ ................................ ...............  22 
6 STUDY MEDICATION ................................ ................................ ................................ ...........................  24 
6.1 DESCRIPTION  ................................ ................................ ................................ ................................ ...... 24 
6.1.1  Packaging  ................................ ................................ ................................ ................................ ...... 24 
6.1.2  Labeling  ................................ ................................ ................................ ................................ ........  24 
6.1.3  Dosing  ................................ ................................ ................................ ................................ ...........  24 
6.1.4  Treatment Compliance and Adherence  ................................ ................................ .........................  25 
6.1.5  Drug Accountability  ................................ ................................ ................................ ......................  25 
7 SAFETY MANAGEMENT  ................................ ................................ ................................ .....................  26 
7.1 CLINICAL ADVERSE EVENTS  ................................ ................................ ................................ ..............  26 
7.2 ADVERSE EVENT REPORTING  ................................ ................................ ................................ .............  26 
7.3 DEFINITION OF AN ADVERSE EVENT  ................................ ................................ ................................ .. 26 
7.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ...........  26 
7.4.1  Relationship of SAE to study drug or other intervention  ................................ ...............................  27 
7.5 ANTICIPATED SAE S ................................ ................................ ................................ ...........................  27 
7.6 IRB/IEC  NOTIFICATIO N OF SAE S AND OTHER UNANTICIPATED PROBLEMS  ................................ ...... 28 
7.6.1  Follow- up report  ................................ ................................ ................................ ...........................  28 
7.7 MEDICAL EMERGENCIES  ................................ ................................ ................................ ....................  28 
8 STUDY ADMINISTRATION  ................................ ................................ ................................ .................  30 
8.1 TREATMENT ASSIGNMENT METHODS  ................................ ................................ ................................ . 30 
8.1.1  Randomization................................ ................................ ................................ ...............................  30 
8.1.2  Blinding  ................................ ................................ ................................ ................................ .........  30 
8.1.3  Unblinding ................................ ................................ ................................ ................................ .... 30 
8.2 DATA COLLECTION AND MANAGEMENT  ................................ ................................ ............................  30 
8.3 CONFIDENTIALITY  ................................ ................................ ................................ ..............................  31 
8.4 REGULATORY AND ETHICAL CONSIDERATIONS  ................................ ................................ ..................  31 
8.4.1  Data and Safety Monitoring Plan  ................................ ................................ ................................ . 31 
8.4.2  Risk Assessment  ................................ ................................ ................................ .............................  32 
8.4.3  Potential Benefits of Trial Participation  ................................ ................................ .......................  36 
8.4.4  Risk-Benefit Assessment  ................................ ................................ ................................ ................  36 
8.5 RECRUITMENT STRATEGY  ................................ ................................ ................................ ..................  37 
8.6 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ................................ ............................  37 
8.7 PAYMENT TO SUBJECTS /FAMILIES  ................................ ................................ ................................ ...... 38 
8.7.1  Reimbursement for travel, parking and meals  ................................ ................................ ..............  38 
8.7.2  Payments to parent for time and inconvenience (i.e. compensation)  ................................ ............  [ADDRESS_443548] for time, effort and inconvenience (i.e. compensation)  ................................ . [ADDRESS_443549]  Adverse drug reaction  
AE Adverse Event  
AUC  Area under the curve (concentration over time)  
BID Twice daily  
BMI  Body Mass Index  
CBC  Complete blood count  
CI Confidence interval  
Cmax Peak plasma level of drug (maximum concentration)  
COX -1 Cyclooxygenase -1 
COX -2 Cyclooxygenase -2 
CRF  Case report form  
CYP2C9  Cytochrome P isozyme 2C9  
ED Emergency Department  
GI Gastrointestinal  
JIA Juvenile idiopathic arthritis  
JRA Juvenile rheumatoid arthritis  
NOS  Not otherwise specified  
NSAID  Nonsteroidal anti -inflammatory drug  
OA osteoarthritis  
OR Odds ratio  
PACU  Perioperative anesthesia care unit  
PK Pharmacokinetics  
RA Rheumatoid arthritis  
SAE  Serious adverse event  
SAN  Storage area network  
SSRI  Selective serotonin reuptake inhibitor  
T1/[ADDRESS_443550]  
Context :  
Tonsillectomy is one of the most common pediatric surgical procedures in the [LOCATION_002].  
Postoperative pain is substantial, with typi[INVESTIGATOR_356108] 1- [ADDRESS_443551] used celecoxib, a selective inhibitor of 
cyclooxygenase- 2, which  should provide pain relief without  increasing bleeding risk.   
Objectives:  
The primary objective is to evaluate efficacy of celecoxib  for pain control after 
tonsillectomy in children.  The secondary objective is to assess safety in regard to 
postoperative hemorrhage and adverse events.  
Study Design:  
Randomized , double -blind, placebo -controlled trial.  Subjects will take acetaminophen plus 
either celecoxib or placebo in regular scheduled doses, and will supplement as needed with 
standard of care analgesic therapy (oxycodone/acetaminophen) . 
Setting/Participants:  
Subjects are healt hy children aged  3 to 11 years who undergo tonsillectomy with or witho ut 
adenoidectomy at any CHOP location.  Subjects with coagulation disorders are excluded.  
Approximately 300 subjects will be enrolled, 150 in each treatment group. 
Study Interventions and Measures :  
Subjects are provided celecoxib  or placebo in scheduled doses every 12 hours for 5 days, 
then continue until they are pain- free, for a maximum of 10 days.  Throughout the study, 
they are allowed to use oxycodone/acetaminophen as needed for additional pain control, 
following standard clinical care .  Acetaminophen is used around the clock for the first [ADDRESS_443552] pain levels on validated 
pain scale instruments, quantity of narcotic medication and acetaminophen required, and 
time to return to normal diet.  All  Emergency Department and hospi[INVESTIGATOR_356109] 30 postoperative days are recorded, noting incidence of  excess pain, dehydrat ion, 
hemorrhage, and other complications . 
Pain control efficacy is assessed by [CONTACT_356134], and  total quantity of rescue pain medication consumed .  Rates of 
hospi[INVESTIGATOR_356110], and the need for operative control, are 
also compared between groups.  
 
    
   
   vii 
PROTOCOL SYNOPSIS 
Study Title  Celecoxib for Pain Management after Tonsillectomy   
Funder  [COMPANY_007] and Children’s Surgical Associates  
Clinical Phase  N/A 
Study Rationale Tonsillectomy is one of the most common pediatric surgical 
procedures in the [LOCATION_002].  Postoperative pain is substantial, 
with typi[INVESTIGATOR_356108] 1- [ADDRESS_443553] used celecoxib, a selective 
inhibitor of cyclooxygenase- 2, which should provide pain relie f 
without increasing bleeding risk .  We aim to determine if celecoxib 
can reduce postoperative pain and narcotic usage in this population, 
without increasing risk of hemorrhage. 
Study Objective( s) Primary   
To measure efficacy of celecoxib for pain control  after 
tonsillectomy .  The primary measure s of pain control will be the 
total quantity of rescue medication consumed, and total number of 
days requiring rescue medication.  
Secondary  
• To evaluate surrogate measures of pain control, including 
time to return to normal diet,  rates of pain -related 
complications and admissions (e.g., dehydration) . 
• To evaluate  safety in regard to rates of postoperative 
hemorrhage and adverse events.  
• To evaluate tolerability of celecoxib for short term 
administration in this popula tion. 
Study Drug  
 Celecoxib , as a suspension 100 mg/5mL .  Dosing is  6 mg/kg BID 
(maximum 300 mg BID) . 
Study Design 
 Randomized,  double -blind, placebo -controlled trial.  Subjects will 
take acetaminophen plus either celecoxib or placebo in regular 
scheduled doses for [ADDRESS_443554] of care analgesic therapy (oxycodone/acetaminophen).   
Subject Population Inclusion Criteria  
1. Males and females age 3 to 11 years inclusive .   
    
   
   viii 
key criteria for 
Inclusion and 
Exclusion:  
 
 2. Scheduled to undergo tonsillectomy (with or without 
adenoidectomy). 
3. Weight ≥  10 kg. 
4. Girls ≥  [ADDRESS_443555] a negative urine/serum 
pregnancy test on the day of surgery and must use an 
acceptable method of contraception, including abstinence, a 
barrier method (diaphragm or condom), Depo- Provera, or an 
oral contraceptive, for the duration of the study.  
5. Parental/guardian permission (informed consent) and if 
appropriate, child assent.  
Exclusion Criteria  
1. Prior tonsillar surgery.  
2. Concomitant surgical procedure that adds more than mild 
additional pain.  Note: ear tubes are always permissible.  
3. Coagulation disorder, or any other hematologic disorder that 
affect s clotting  or results  in anemia.  
4. Moderate to severe asthma, defined as subjects who either 
(1) have daily symptoms requiring daily use of short -acting 
bronchodilators, or (2) had  an exacerb ation in the last 3 
months requiring admission , ED visit , or systemic 
corticosteroid administration.  
5. Any degree of aspi[INVESTIGATOR_248]- sensitive asthma, or any history of 
asthma exacerbation caused by [CONTACT_356135].  
6. Severe obstructive sleep apnea that requires use of  CPAP  or 
BiPAP.  
7. Significant chronic pulmonary disease, defined as subjects 
requiring oxygen therapy, ventilator support, or positive 
pressure therapy.  
8. Significant cardiac disease, defined as any one of the 
following: cardiovascular disease, structural cardiac 
anomalies, prior cardiac surgery, or requirement for cardiac 
anesthesia.   
9. Severely obese (BMI > 9 9th percentile for age).  
10. History of hepatic or renal disease, or condition that impairs 
hepatic or renal function . 
11. Juvenile rheumatoid arthritis (JRA).  
12. History  of GI bleeding, or chronic GI condition that would 
increase risk of bleeding, ulceration, or perforation. 
    
   
   ix 
13. Hypertension.  
14. Craniofacial syndromes.  
15. Syndrome or neurologic condition that would hinder 
accurate assessment of postoperative pain.  
16. Inability to feed orally or take oral pain medication. 
17. Chronic pain disorders, or otherwise requiring pain 
medication more than once weekly . 
18. Laboratory abnormalities on the preoperative CBC:  
Hemoglobin  < 9 gm/dL  
Platelet count < 100,000/mm3 
19. Any investigational drug use within 30 days prior to 
enrollment.  
20. Pregnant or lactating females.  
21. Parents/guardians or subjects who, in the opi[INVESTIGATOR_684], may be non- compliant with study schedules or 
procedures.  
22.  Hypersensitivity or allergic reactions to celecoxib, aspi[INVESTIGATOR_248], 
or other NSAIDs, including asthma flare ups . 
23. Allergy to sulfonamides  or calcium carbonate . 
Number Of Subjects  
 Total [ADDRESS_443556]’s participation will last from [ADDRESS_443557] 1 year.  
Study Phases  
    (1) Screening : screening for eligibility and consent  obtained.  This 
is done at the pre -operative office visit.  
(2) Study Drug Treatment : After surgery, subjects consume study 
medication every 12 hours for 5 days, then until pain- free, for a 
maximum 10 days. 
(3) Follow -Up: Admissions to ED or hospi[INVESTIGATOR_356111] [ADDRESS_443558] 
for this study. 
 
 xi   
   
   TABLE 1: SCHEDULE OF  STUDY PROCEDURES  
Study Phase  Screening  Treatment  Follow -up 
Visit / Activity  Before 
Surgery  Surgery 
Day Treatment 
(home)  Call 1  Treatment 
(home)  Home  
Observation  Call 2  Call 3  
Postoperative Day   0 1-5 3(+/-1) 6-10 11-14 14(+/ -1) 30 (+/ -2) 
Informed Consent/Assent  X        
Review Inclusion/Exclusion 
Criteria  X        
Demographics/Medical 
History  X        
Physical Examination  X1        
Vital Signs: BP, HR, RR   X2       
Height and Weight  X1        
Pregnancy Test   X2       
Prior/Concomitant 
Medications  X1 X2       
CBC with platelets   X1        
Randomization  X        
Dispense Study Drug   X       
Administer Study Drug   X X X X3     
Acetaminophen   X X X PRN  PRN    
Oxycodone   PRN  PRN  PRN  PRN  PRN    
Diary - Pain, Narcotic use, 
diet, fluid intake, urine output   X X X X X   
Drug compliance     X   X  
Drug accountability        X  
Adverse Event  Assessment     X4   X X 
 xii   
   
    
Notes 
1- These are clinical care; they are recorded from the preoperative office visit.  
2- Recorded from perioperative records.  Pregnancy testing for females of childbearing potential is always done as part of clinical care  before surgery  in the 
preoperative area . 
3- Duration of study drug is until child is pain-free  (see text) , or the maximum of [ADDRESS_443559] common pediatric surgical procedures in the [LOCATION_002].  
Postoperative pain is substantial, with typi [INVESTIGATOR_356108] 1- 2 weeks after surgery.  Ibuprofen has been  used by [CONTACT_356136], and has proven effective for pain control .  However, ibuprofen 
inhibits platelet function, a nd the possibility that it might increase risk of postoperative 
bleeding, combined with equivocal data regarding its safety, has limited  its widespread 
adoption in this setting .  Tonsillectomy carries a significant bleeding risk of 2 -5%, and 
hemorrhage eve nts are often emergent situations, since they typi[INVESTIGATOR_95469]  1-[ADDRESS_443560] -tonsillectomy pain.  Celec oxib is a newer 
nonsteroidal anti -inflammatory drug (NSAID) that is a selective inhibitor of 
cyclooxygenase- 2. Because platelet inhibition is mediated via cyclooxygenase -1, celecoxib 
should provide pain relief without increasing bleeding risk like traditio nal NSAIDs .  We 
hope to employ this drug as a key element in post -tonsillectomy management, and this study 
represents the first step in evaluating its efficacy and safety. Specifically, we aim  to 
determine if celecoxib can reduce postoperative pain and narcotic usage after tonsillectomy , 
without increasing risk of hemorrhage.  
1.[ADDRESS_443561] or Intervention 
The study drug is celecoxib. Celecoxib is a nonsteroida l anti -inflammatory drug with anti -
inflammatory, analgesic, and antipyretic activities. Its  mechanism of action is by [CONTACT_356137], primarily via inhibition of cyclooxygenase -2 (COX- 2), and at 
therapeutic concentrations in humans, celecoxib does not inhibit the cyclooxygenase -1 
(COX- 1) isoenzyme .  
Celecoxib is approved by [CONTACT_356138] 2 and older for treatment of 
juvenile rheumatoid arthritis .  Celecoxib is on the CHOP formulary for use in (1) patients >= 
2 years  old for JRA, (2)  patients >= 12 years old and >=[ADDRESS_443562] increased risk for 
GI adverse effects or bleeding concerns precluding use of traditional NSAIDs, and (3) 
oncology patients with surface area >= 0.4 square meters for anti -angiogenesis .  Celeco xib is 
approved by [CONTACT_356139], acute/ 
postoperative pain, and primary dysmenorrhea , and has been widely used since its 
introduction in 1998. 
1.3 Findings from Clinical Studies  
1.3.1 Clinical Studies  
[IP_ADDRESS] Human Pharmac okinetics  
The following are adapted  from the Full Prescribing Information for Celebrex ([COMPANY_007], Inc).  
 
   
   2 
Absorption : Peak plasma levels of celecoxib occur  approximately 3 hrs after an oral dose. 
Under fasting  conditions, both peak plasma levels (C max) and ar ea under the  curve (AUC) 
are roughly dose -proportional up to 200 mg BID;  at higher doses there are less than 
proportional increases in  Cmax and AUC .  Absolute bioavailability  studies have not been 
conducted.  With multiple dosing, steady- state conditions are reached on or before Day 5. 
The pharmacokinetic parameters of celecoxib in a group of healthy adult subjects are sho wn 
in Table 2 below .  
 
Table 2  : Summary of Single Dose (200 mg) Disposition  Kinetics of Celecoxib in 
Healthy Adult Subjects   
 
 
 Subjects  under  fasting conditions  (n=36 , 19-52 
yrs.) 
 
 
 
Kinetics of suspension formulation and sprinkled capsules:   In healthy adult volunteers, the 
overall systemic exposure  (AUC) and C max of celecoxib was equivalent when celecoxib was 
administered as an intact capsule, as capsule contents sprinkled on applesauce , or as a 20 
mg/mL oral suspension. There were no significant alterations in  Cmax, Tmax or t 1/2 after 
administration of capsule contents on  applesauce [Krishnaswami et al  2012] .   
Distribution : In healthy subjects, celecoxib is highly protein bound (~97%) within the 
clinical dose range. In vitro studies  indicate that celecoxib binds primarily to albumin and, to 
a lesser extent, α 1-acid glycoprotein.  The apparent volume of  distribution at steady state 
(Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.   
Metabolism : Celecoxib metabo lism is primarily  mediated via CYP2C9. Three metabolites, a 
primary  alcohol, the corresponding carboxylic acid and its  glucuronide conjugate, have been 
identified in human plasma. These metabolites are inactive as COX -1 or COX- 2 inhibitors.  
Excretion : Celecoxib is eliminated predominantly by [CONTACT_356140] (<3%) 
unchanged drug recovered in the  urine and feces. Following a single oral dose of 
radiolabeled  drug, approximately 57% of the dose was excreted in the  feces and 27% was 
excreted i nto the urine. The primary metabolite in both urine and feces was the carboxylic 
acid metabolite (73% of dose) with low amounts of the glucuronide  also appearing in the 
urine. It appears that the low solubility  of the drug prolongs the absorption process m aking 
terminal half- life (t 1/2) determinations more variable. The effective half -life is approximately 
11 hours under fasted conditions. The  apparent plasma clearance (CL/F) is about 500 
mL/min.    
Pediatric  Pharmacokinetics :  
Single -dose and steady -state pharmacokinetics were investigated in 10 children aged 6 -16 
receiving celecoxib over a 1 week period for anti -angiogenesis [Stempak et al 2002].  The 
drug was absorbed and distributed similarly as adults, but was metabolized much faster.  Mean (%CV ) PK Paramete r Values  
Cmax, ng/mL  Tmax, hr Effectiv e t1/2, hr Vss/F, L CL/F , L/hr 
705 (38) 2.8 (37) 11.2 (31) 429 (34) 27.7 (28) 
   
   [ADDRESS_443563] as adults, and had a half -life 
approximately half as long (3.7 hours compared to 8.9 hours).  These findings led the 
authors to conclude that higher or more frequent dosing may be needed in chil dren, rather 
than simply the use of weight -adjusted adult dosing. 
The steady state pharmacokinetics of celecoxib  administered as an investigational oral 
suspension was  evaluated in 152 JRA patients 2 years to 17 years of age  weighing ≥10 kg 
with pauciartic ular or polyarticular course  JRA and in patients with systemic onset JRA.  
Population pharmacokinetic analysis indicated that the oral clearance (unadjusted for body 
weight) of celecoxib increases less than  proportionally to increasing weight, with [ADDRESS_443564] 40% and 24% lower clearance,  respectively, compared with 
a 70 kg adult RA patient.  Based on these data, the manufacturer recommends t wice -daily 
administration of 50 mg capsules to JRA patients  weighing ≥10 to ≤25 kg and 100 mg 
capsules to JRA patients weighing >25 kg to  achieve plasma concentrations similar to those 
observed in a clinical trial that demonstrated  the non- inferiority of celecoxib to naproxen 
(see Clinical Studies in Children, below ). Celecoxib has  not been studied in JRA patients 
under the age of 2 years, in patients with body weight less than 10 kg (22 lbs), or beyond 24 
weeks duration of therapy.   
Platelet  pharmacodynamic s: In clinical trials using normal volunteers,  celecoxib  at single 
doses up to 800 mg and multiple doses  of 600 mg twice daily for up to 7 days duration 
(higher than recommended therapeutic doses) had no effect on reduction of platelet 
aggregati on or increase in bleeding time .  
[IP_ADDRESS] Clinical Studies in Adults  
Celeco xib h as been well studied in adults and is widely used in the management of 
rheumatoid arthritis and osteoarthritis  (OA) .  In knee and hip OA, celecoxib was evaluated 
in placebo-  and active -controlled clinical trials of up  to 12 weeks duration. Treatment  with 
celecoxib  100 mg twice daily or 200 mg once daily resulted in improvement in pain, 
stiffness, and functional measures in OA.   In three 12- week  studies of pain accompanying 
OA flare, celecoxib  doses of  100 mg twice daily and 200 mg twice daily provided 
significant reduction of pain within 24- 48 hours of initiation of  dosing [Celebrex Full 
Prescribing Information,  [COMPANY_007]  Inc.]  
Celecoxib has also been studied in adults for managing acute pain after surgery, and in 
primary d ysmenorrhea.  In acute analgesic models of post -oral surgery pain, post -orthopedic 
surgical pain, and primary dysmenorrhea, celecoxib  relieved pain that was rated by [CONTACT_356141].  Single doses provided pain relief within 60 minutes. [Celebrex Full 
Prescribing Informati on, [COMPANY_007] Inc.]  Li et al [2009] studied 51 adults over 55 years of age 
receiving total hip replacement, randomized to diclofenac, rofecoxib, or placebo.  Overall, 
ADRs were similar between the two NSAIDs.  Rofecoxib resulted in less  perioperative 
blood l oss compared to diclofenac (7% increase over placebo with rofecoxib, vs. 32% 
increase over placebo with diclofenac).  
Adverse drug reactions (ADRs) of celecoxib appear to be similar to other NSAIDs.  Upper 
GI bleeding is a known risk of chronic  NSAID therap y.  In a large population- based, nested 
case- control analysis of 10,892 adults, Hippi[INVESTIGATOR_356112] -Cox et al  [2005] studied rates of first -ever 
   
   4 
adverse upper GI events.  The COX- 2 inhibitors (rofecoxib or celecoxib) were found 
comparable  to the traditional NSAIDs (ibuprofen, diclofenac, and naproxen).  For further 
discussion of adverse reactions, see Section 9.4 below.   
Adverse Events from the analgesia and d ysmenorrhea  studies: Approximately 1,[ADDRESS_443565]-oral surgery pain (single  dose ), and of 
analgesia and dysmenorrhea ( up to 600 mg/day) . The types of adverse  events were similar to 
those reported in arthritis studies. The only additional adverse event reported was post -
dental extraction  alveolar ost eitis (dry socket) in the post -oral surgery pain studies . For 
further discussion of adverse reactions, see Section 9.4 below.   
[IP_ADDRESS] Clinical Studies in Children  
Celecox ib has been studied in children, mainly with juvenile rheumatoid arthritis , and was 
found to be effective and well tolerated.  Foeldvari et al [ 2009] studied celecoxib at [ADDRESS_443566] 9 kg, compared to naproxen, for 12 weeks, 
with a 12- week open label extension.  The drug was given as a suspension (10 mg/mL or 20 
mg/mL for the low and high- dose groups, respectively). Celecoxib was non- inferior to 
naproxen for efficacy , and safety data (adverse events) were  comparable between groups.  
This was true even with fairly high dosages in the high- dose group -- 6 mg/kg BID 
(maximum of 300 mg BID). The most common (> 5%) adverse events were headache, fever , 
upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea 
and vomiting. Similar AEs and rates were seen in the naproxen -treated s ubjects.   The 
incidence of AEs in the  12-week, open- label extension was similar during the double  blind 
study, and this was at the higher celecoxib dose (6 mg/kg BID).   
Murto et al [2015] studied celecoxib in 282 children age 2- 18 who underwent tonsillec tomy.  
This study used a loading dose of 6 mg/kg preoperatively followed by 3 mg/kg BID on 
postoperative days 0- 2.  The drug was given as a suspension (10 mg/mL). Celecoxib was 
effective for pain reduction and was well -tolerated, with no difference in adve rse events 
between the celecoxib and placebo groups.  The results are detailed further in Section 1.5, 
“Use after tonsillectomy,” below.   
Sobel et al [2014] compared s afety of celecoxib and ibuprofen from  a Phase- 4 registry  in 
274 children 2- 17 years with JIA/JRA.  Again, adverse drug reactions (ADRs) were 
comparable; no bleeding events were reported.  In a retrospective review of ADRs, Titchen 
et al [2005] compared several NSAIDs in [ADDRESS_443567] 
NSAIDs.   Finally in a Cochrane Review, Derry et al [2013] report [ADDRESS_443568] been used in several large studies in children.  The trials in 
children with both JRA and tonsillectomy, detailed above, used suspensions of 10 or 20 
mg/mL  made at the local institutions [Foeldvari et al 2009, Murto et al 2015]. The 
suspen sions are stable at least 93 days at either room temperature or refrigerated [Donnelly 
et al 2009].  Pharmacokinetic analysis has been performed in both adults and children 
[Krishnaswami et al 2012], showing drug bioavailability in the suspensions that was 
equivalent to capsule or sprinkle administration.  
Dosage endorsed by [CONTACT_356142]  50 mg BID for weight 10 kg to <= 25 
kg, and 100 mg BID for weight  >25 kg.  This is approximately 3 mg/kg BID, which was the 
dose used in the recent pediat ric tonsillectomy trial by [CONTACT_356143] [2015], and was also the 
lower dose group in the pediatric JRA trial [Foeldvari 2009].  However, the conclusion of 
the Murto group was that this dose is too low to produce  major  relief of the acute pain after 
tonsillectomy .  Citing the PK study by [CONTACT_356144] [2002] showing shorter half life and more 
rapid clearance in children, the authors recommended higher dosing for tonsillectomy and a 
longer duration of therapy.   
Indeed, much higher doses have been well tolerated in children.  As noted earlier, the higher 
dose group in the Foeldvari study (6 mg/kg BID) had rates of adverse events comparable to 
the lower dose group, even when given well over 12 weeks .  Furthermore, the PK study by 
[CONTACT_356145] [2002] used even  higher doses ( average 8.6 mg/kg BID, range  7-12 mg/kg 
BID) for over one week in 10 cancer patients aged 6- 16, with no reported toxicity.  
Based on data from all the studies in children, our dosing for the present study is a s follows.  
Children will receive 6 mg/kg BID  (maximum 300 mg BID)  for the duration of their acute 
pain, up to a maximum of 10 days.  We will formulate study drug into a suspension 
following the method of Donnelly et al [2009], except with a 20 mg/mL concentration to 
facilitate the current dosing.  The latter concentration was used effectively in the JRA trial as 
well.  Subjects  will receive their first dose just before surgery, following Murto et al [2015].  
 
1.5 Relevant Literature and Data 
Background  
Pain management after pediatric adenotonsillectomy remains a significant health care 
problem [ Baugh et al, AAO -HNSF Clinical Practice Guideline,  2011].   Historically, pain 
has been managed with opi[INVESTIGATOR_858], but recently there has been increased interest in reducin g the 
use of opi[INVESTIGATOR_356113], particularly following the recent FDA black- box warning that 
followed reports of deaths in children treated with codeine after tonsillectomy, who had an 
uncommon genetic variant causing hypermetabolism of codeine [ Kuehn 2013].    
   
   [ADDRESS_443569] hemorrhage of 2- 5%, there has been reluctance nationally to 
adopt widespread use of NSAIDs for this indication, based on the tendency of traditional 
nonselective NSAIDs to inhibit platelet function, and thus possibly increase bleeding risk. 
At this time, the literature remains equivocal about the safety of traditional NSAIDs 
regarding postoperative bleeding risk.  In a 2011 Practice Guideline published by [CONTACT_356146]- Head & Neck  Surgery, conflicting evidence was 
presented.  A Cochrane review of 13 randomized trials involving 955 children requiring 
surgical intervention for bleeding, and 7 trials involving 471 children not requiring surgical 
intervention, found that NSAIDs did not  significantly incre ase bleeding risk [ Cardwell et al 
2005]. F urthermore, a meta -analysis found increased risk from use of aspi[INVESTIGATOR_248], but not for 
nonaspi[INVESTIGATOR_356114] [ Krishna et al, 2003 ].  On the other 
hand, another systematic  review found some evidence for increased risk of reoperation for 
bleeding in patients given NSAIDs postoperatively [ Møiniche  et al 2003].    
Importantly, since that publication, an updated Cochrane review was publishe d [Lewis et al, 
2013] . There were 15 studies involving 1101 children in this updated review.  Fourteen 
studies compared NSAIDs with other analgesics or placebo and reported on bleeding 
requiring surgical intervention. The use of NSAIDs was associated with a nonsignificant 
increase in the risk of bleeding requiring surgical intervention: Peto odds ratio (OR) 1.69 
(95% confidence interval (CI) 0.71 to 4.01). In 10 studies involving 365 children, NSAIDs 
did not significantly alter the number of perioperative bleeding events requiring non -surgical 
intervention: Peto OR 0.99 (95% CI 0.41 to 2.40), but the confidence intervals did not 
exclude an increased risk.  The Cochrane group concluded that “there is insufficient 
evidence to exclude an increased risk of bleeding when NSAIDs are u sed in paediatric 
tonsillectomy ”[Lewis et al,  2013]. 
CHOP e xperience with NSAIDs  post -tonsillectomy  
For approximately [ADDRESS_443570] to 
pain management for tonsillectomy patients.  Though primary pain management remained 
acetaminophen and oxycodone, patie nts were instructed to add the i buprofen if they 
experienced breakthough pain.   Ibuprofen was also commonly used in- house, in younger 
patients admitted postoperatively for observation.  Indeed, it was quite successful as a  rescue 
medication, with successful resolution of pain escalations requiring calls to phone triage, as 
well as significant reduction in pain calls overall ( unpublished internal review, summer 
2013).  However, a possible rise in overall rates of postoperati ve hemorrhage was observed 
during the ibuprofen period, and also in rates of bleeding requiring re -operation.   In a 4 
month period reviewing 696 tonsillectomy cases, overall events were 33/696 = 4.7%, 
including 20 (3.5%) requiring re -operation (unpublishe d internal review, Spring 2014) .  
These were slightly increased over historical rates in our Division of about 3- 4% and 2%, 
respectively.  Importantly, during that time ibuprofen status of each individual patient was 
not documented, so it is unclear how ma ny of these cases were actually using rescue 
   
   [ADDRESS_443571] care at CHOP is  oxycodone (0.075 mg/kg/dose) and acetaminophen  (15 
mg/kg/dose), as liquid formulations for all ages.  Both are officially prescribed as every [ADDRESS_443572] few days, until their pain 
becomes less intense.  The number of days are not specified.  Patients then switch to using 
both as -needed.  The only patients not routinely advised to use around- the-clock dos ing are 
the very young infants and toddlers (under age 3).  
Patients are instructed to call the phone triage nurses if they experience uncontrolled pain at 
home.  In that case, the phone triage nurse first confirms the patient is taking their 
acetaminophen  and oxycodone.  Their  oxycodone dose is  then increased as necessary up to 
0.1 mg/kg/dose every 4 hours, with referral to the ED if pain is still not controlled.  Review 
of phone triage logs revealed over 24% of patients called with pain issues, and 7- 8% 
required up- dosing of oxycodone ( Internal QI data, March 2013 ). 
Celecoxib as a possibly safer alternative  
Celecoxib is a  selective inhibitor of cycloox ygenase -2.  As such, it provides the pain control 
of traditional, nonselective NSAIDs, but without their side effect of platelet inhibition, 
which is mediated through COX -1.  Celecoxib is widely used in the management of pain of 
rheumatoid arthritis and osteoarthritis in adults, and is FDA -approved in children 2 years 
and older and > 10 kg for management of j uvenile rheumatoid arthritis  (see Clinical Studies,  
above) .   It is currently on the CHOP Formulary for this indication.   
Use after tonsillectomy  
There is limited data on use of Cox- 2 inhibitors after surgery in children, including 
tonsillectomy.   Before  it was withdrawn from the market, another Cox -2 inhibitor, 
rofecoxib, was administered to children successfully with no increase in bleeding rates 
observed [Joshi et al 2003].  Rofecoxib, which was available as a liquid formulation, was 
   
   8 
pulled from the ma rket in 2004 over  concern s for increased risk of myocardial infarction in 
adults  with coronary artery disease.  
In adults, several small studies found celecoxib to be safe and effective after tonsillectomy.   
A small study of 120 adults in Finland compared c elecoxib capsules to ketoprofen, a 
nonselective NSAID, after tonsillectomy.  While ketoprofen provided a better initial pain 
control, after discharge, recovery with celecoxib was faster and the rate of secondary 
hemorrhage was lower (<1%,  vs. 6% with keto profen) [Nikanne et al 2005].   The 
University of Iowa also reported a small study of celecoxib capsules after tonsillectomy in 
adults (N=18, randomized, placebo -controlled).  In this small cohort, celecoxib reduced 
postoperative narcotic and acetaminophen  requirements compared to placebo; no 
postoperative hemorrhages were noted in either group. [Van Daele et al, 2014]  
Celecoxib itself has not yet been widely used for pediatric tonsillectomy, likely due to the 
fact that a liquid formulation is not yet commercially available.  The Children’s Hospi[INVESTIGATOR_356115], which it now uses it as its primary 
regimen for pain control (S. Kherani MD, personal communication).   The suspension is 
stable for 90 days and its details were published [Donnelly et al, 2009].   
The CHEO group recently completed a randomized trial comparing celecoxib to placebo in 
282 children after tonsillectomy [Murto et al, 201 5].  Celecoxib was given as  a loading dose 
of 6 mg/kg just prior to surgery, followed by 3 mg/kg BID for 5 more doses.  They used 
their in -house suspension of 10 mg/mL referenced above.  The 3 mg/kg dose  was chosen as 
it closely approximates that recomm ended for children with JRA.  Pain scores were found to 
be significantly lower in the celecoxib group, though the reductions were only modest  (11% 
reduction in worst pain levels for postoperative days 0- 2).  Co -analgesic consumption was 
also modestly but s ignificantly reduced (20% less consumption of acetaminophen and oral 
morphine).  Notably, the dosing period was very short (2 days) , after which  pain scores 
rebounded to levels equal to or greater than placebo, for the duration of the postoperative 
recover y.  In this trial, celecoxib was found safe and well tolerated, with rates of adverse 
events, including bleeding, no different from placebo. 
Of interest, the group separately analyzed the data from the 7.4% of their cohort who were 
genetically slow metabol izers of celecoxib (CYP2C9*3 heterozygotes ).  Children in this 
subgroup receiving celecoxib showed greater relief of pain, and for a longer duration, than 
those with the normal genotype .   
In summary, the authors found:  (1) only modest pain reduction, followed by [CONTACT_356147], when children were given standard celecoxib dosing (which was developed based 
on JRA patients); (2) an excellent safety profile; (3) better pain control in the slow 
metabolizers.  These findings, combined with prior data showing  celecoxib to have  more 
rapid clearance in children compared to adults  [Stempak 2002, detailed above ], led the 
authors to conclude that different doses should be used after tonsillectomy.  They 
recommended a higher dose of the drug, and for longer dura tion, to ensur e more effective 
pain control in this setting.   Finally, noting the synergy of acetaminophen with NSAIDs, 
   
   9 
they also recommended adding supplemental acetaminophen “around the clock,” as the 
combination may provide greater analgesic effects.   
Summary of c urrent e vidence and r ationale  
The available evidence regarding safety of ibuprofen after tonsillec tomy  remains equivocal, 
even after several systematic reviews and meta- analyses.  Additionally, CHOP 
Otolaryngology has clinically observed increa sed severity of bleeding events in patients who 
received ibuprofen.   These observations support the search for a safer alternative for pain 
management.  The ideal drug would decrease narcotic usage in children, while not 
increasing bleeding rates over tra ditional regimens (narcotic+ acetaminophen), be well -
tolerated , and have  experience in its use in children.  Celecoxib satisfies these criteria , with 
enough preliminary data to suggest it is effective for pain control while not increasing 
bleeding risk.  Furthermore, recent pediatric data  confirm it is safe and  effective after 
pediatric tonsillectomy, and confirm the efficacy and safety  of an oral suspension.  
However, the fact that  benefits were only modest  under the  current approved dosing for  
chronic use  in JRA , suggest s that  higher doses are needed in children undergoing this 
surgical procedure.  This the rationale for the doses used the present study.  
1.6 Compliance Statement  
This study will be conducted in full accordance all applicable Children’s Hospi[INVESTIGATOR_356116]: Consolidated Guideline approved by [CONTACT_20417] (ICH ). All  epi[INVESTIGATOR_1865] s of noncomplianc e will be 
documented. 
The investigators will perform the study in accordance with this protocol, will obtain 
consent and assent, and will report unanticipated problems involving risks to subjects or 
others  in accordance with The Children’s Hospi[INVESTIGATOR_356117]. Collection, recording, and reporting of data will be 
accurate and will ensure the privacy, health, and welfare of research subjects during and 
after the study.  
2 STUDY OBJECTIVES 
The purpose  of the study is to determine the efficacy and safety of celecoxib when used for 
pain control after tonsillectomy.  
2.1 Primary Objective 
The primary objective of this study is to determine whether celecoxib reduces pain in 
children 3 to 11 years after tonsille ctomy .  The primary measures  of pain control will be 
total quantity of rescue pain medication used, and number of days on rescue medication. 
2.2 Secondary Objectives 
The secondary objectives are to:  
   
   10 
• Determine whether celecoxib shortens  time to return to normal diet .   
• Determine whether celecoxib reduces pain -related complications and readmissions (e.g. 
admissions for dehydration, calls or ED admissions for excessive pain).  
• Determine whether celecoxib increases rate of post -tonsillectomy hemorrhage compared 
to placebo.  
• Evaluate the tolerability of celecoxib for short- term admini stration after tonsillectomy . 
• Evaluate safety in terms of rates of other adverse events.  
[ADDRESS_443573] of c are 
analgesic therapy (oxycodone/acetaminophen).  Subjects record pain scores, narcotic 
consumption, and type of diet daily for 14 days.  Follow up telephone calls are performed by 
[CONTACT_356148], and by [CONTACT_356149] y period (2 weeks), 
and at [ADDRESS_443574] surgery .  Potential subjects  are screened  for inclusion and exclusion 
criteria, then the study is explained, including the randomization scheme, risks, benefits, and 
alternatives, then subjects are approached for infor med consent / assent .  Subjects who 
consent/assent to the study are randomized to either study drug or placebo prior to surgery . 
Parental/guardian permission (informed consent) and, if applicable, child assent, will  be 
obtained prior to any study- related procedures being performed.  Note that b lood samples 
(CBC with platelets) are  drawn  on all subjects as part of clinical care, and all females of 
childbearing potential undergo a preoperative urine pregnancy test on the day of surgery, 
also as clinical care.  
3.1.2 Study Treatment Phase  (Postop day 0 until pain -free, maximum 10 days)  
This Phase includes the day of surgery (Day 0), and up to [ADDRESS_443575] -anesthesia care 
   
   11 
unit, then are either discharged to home (Day Surgery), or are admitted for inpatient 
observation as per clinical care.  The procedures below are identical for either pathway.   
They then receiv e a dose of study drug that evening, then twice daily thereafter, at [ADDRESS_443576] before each dose of study medication, and as needed 
in between. All subjects take acetaminophen (15 mg/kg/dose) in scheduled doses every [ADDRESS_443577] 5 days.  During those 5 days, any  acetaminophen dose scheduled during 
the early morning hours ( midnight to 6 AM) will be optional if subject is asleep. After [ADDRESS_443578] volume of oxycodone consumed throughout the  2-week recovery period, the 
pain scores,  and time to return to normal diet.  A follow up call by a study nurs e occurs at 
Day 3 (+/ - 1 day) to assess compliance with medication, pain control, compliance with 
symptom  diaries, and adverse events.   
During this phase, subjects take study medication for 5 days, then continue until the point 
they are pain -free, defined  as follows:   At the time a dose of study drug is  due, the subject’s 
pain score is now 0, and has  also been [ADDRESS_443579] 24 hours (total 3 consecutive ‘0’ scores) , 
AND the subject has not required any  rescue medication in prior [ADDRESS_443580] 
subjects will requir e pain medication about 8 days [Sobol et al, 2006] . 
Before discharge, as per clinical care, subjects receive specific instructions to call the 
emergency line if they experience any hemorrhage, even in small amounts.  In addition, 
subjects are instructed to discontinue study medication if they experience either skin rash or 
hemorrhage.  These, or any other  complications occurring during the t reatment an d follow 
up periods (e.g., dehydration ), are managed according to usual  clinical care pathways, 
including referral to the ED as appropriate.  There are no changes to these pathways  related 
to the study.   However, the occur rence and outcomes of such compli cations are recorded for 
study purposes . 
During the treatment period, subjects self -monitor for dehydration, and are treated and/ or 
readmitted as per clinical judgement, which is all standard of care.  This includes  specific 
recording of fluid intake and number of voids each day in the Study Diary.  Additionally, 
these are assessed by [CONTACT_356150] 3 telephone call.  Subjects with  low urine  output 
(less than 1 void every 12 hours ), inadequate  oral intake  (based on weight ), or other clinical 
concern for dehydration are referred to the ED.  Evaluation and management then follow  
established  pathways  (http://www.chop.edu/clinical -pathway/gastroenteritis -and-
dehydration- clinical -pathway ).  Subjects judged to have significant dehydration receive IV 
fluid r ehydration and evaluation of serum electrolytes ; BUN and  creatinine  are also assessed 
per clinical judgement .  All subjects whose dehydration is serious enough to require  IV 
fluids, or who have abnormal serum creatinine  (>1.5X upper limit of normal for age ), will 
discontinue  the study drug  for the duration of the study.  Any abnormalities of electrolytes 
or renal function will be reassessed as per clinical care. These results are all recorded by [CONTACT_58860]. Subjects not requiring IV fluids  or lab draws in the ED will be considered as 
mild dehydration and will continue the study medication, once they demonstrate adequate 
   
   [ADDRESS_443581] 5 days.  Second, while celecoxib has effects within hours, it may 
take up to 5 days for subjects to reach their final steady- state levels of pain con trol (as 
discussed in section [IP_ADDRESS]).  Third, by [CONTACT_356151], [ADDRESS_443582] ate of uncontrolled pain.  
3.1.3 Follow -up Phase  (Discontinuation of study drug to P ostop day 30)  
In clinical practice at CHOP and at most centers, patients do not generally return for 
postoperative follow up visit after tonsillectomy surgery.  This will be  the case for subjects 
in this study as well, with all routine follow up conducted by [CONTACT_24646], without any 
further scheduled Study Visits.   
Between the day they become pain- free and Day 14, subjects no longer take study 
medication, but continue to record pain levels, narcotic usage, and diet.  Subjects receive a 
second follow up call by a study team member on Day 14 (+/ - 1 day) to review compliance 
with medication, and adverse events or complications.  Subjects receive a final call on Day 
30 (+/ - 2 days) to review final outcomes (adverse events, complications) and to ensure return 
of the diaries  to the study team.  
As noted above, any complications during this period are managed per clinical care, with 
their occurrence and outcomes recorded for study purposes.  
3.[ADDRESS_443583]’s current medications.   
Blinding of subjects will be further assured by [CONTACT_356152].  This should not be difficult, as celecoxib 
does not have a characteristic taste [ Krishnaswami et al  2012] . 
Siblings undergoing surgery on the same day will be randomized to the same treatment 
group. 
   
   [ADDRESS_443584] will be up to 4 months.  This includes the screening day, 
the lag time until surgery occurs (varies, but is typi[INVESTIGATOR_897] 0- 3 months), the day of surgery, and 
the postoperative 30 days which include treatment and follow up. 
3.3.2 Total Number of Stud y Sites/Total Number of Subjects Projected  
The study will be conducted only at CHOP . 
Recruitment will stop when there are 180 subjects with evaluable data.    It is expected that 
approximately 300 subjects will be enrolled to produce 180 evaluable subjects (those who 
return their Study Diary and properly log rescue medication consumption) .  
3.4 Study Population  
3.4.1 Inclusion Criteria  
1) Males and females age 3 to 11 years inclusive .   
2) Scheduled to undergo tonsillectomy (with or without adenoidectomy). 
3) Weight ≥  10 kg. 
4) Girls ≥  [ADDRESS_443585] a negative urine/serum pregnancy test on the day of 
surgery and must use an acceptable method of contraception, including abstinence, a 
barrier method (diaphragm or condom), Depo- Provera, or an oral contraceptive, for the 
duration of the study.  
5) Parental/guardian permission (informed consent) and if appropriate, child assent.  
 
The inclusion age range  (3-11 years)  was chosen due to the demographic of the surgical 
population, and in order to reduce for variability in efficacy measures.  First, the large 
majority of tonsillectomy procedures are performed in the younger  age group ( for example, 
between September 2013 thru June 2014, 1421 tonsillectomies were performed  at CHOP  in 
the age 3 -11 group vs. 140 for age >=12).  Second, t he young patients are historically more 
likely to experience readmission due to pain (e.g., dehydration ) ( 40 readmissions vs. 9 at 
CHOP during the same period, respectively).  Third, in clinical experience, adolescent 
patients experience substantially hig her pain levels, and display  much wider variation in 
intensity , narcotic consumption, and outcome measures, such as time out of school or time 
to return to normal diet.  This may be  simply due to behavioral variations in teenagers, but 
may also be  in part due to their  different indications for tonsillectomy (chronic tonsillitis , 
versus mainly sleep disordered breathing in the younger patients ).   Thus, inclusion of 
adolescents would add undesirable variability in efficacy measures.  Fourth, bleeding risk is  
higher in teenagers and adults  [Wei et al, 2000] .  Until the bleeding risk from celecoxib is 
better defined  from studies like this , this fact justifies postponing inclusion  of this older age 
group until a future study .   
   
   14 
3.4.2 Exclusion Criteria  
1) Prior tonsillar surgery.  
2) Concomitant surgical procedure that adds more than mild additional pain.  Note: ear 
tubes are always permissible.  
3) Coagulation disorder, or any other hematologic disorder that affects clotting or results in 
anemia.  
4) Moderate to severe asthma, defin ed as subjects who either (1) have daily symptoms 
requiring daily use of short -acting bronchodilators, or (2) had an exacerbation in the last 
3 months requiring admission, ED visit, or systemic corticosteroid administration.   
5) Any degree of aspi[INVESTIGATOR_248]- sensitiv e asthma, or any history of asthma exacerbation caused by 
[CONTACT_356135].  
6) Severe obstructive sleep apnea that requires use of  CPAP or BiPAP.  
7) Significant chronic pulmonary disease, defined as subjects requiring oxygen therapy, 
ventilator support, or positive pre ssure therapy.  
8) Significant cardiac disease, defined as any one of the following: cardiovascular disease, 
structural cardiac anomalies, prior cardiac surgery, or requirement for cardiac anesthesia.   
9) Severely obese (BMI > 9 9th percentile for age).  
10) History o f hepatic  or renal  disease, or condition that impairs  hepatic or renal function.  
11) Juvenile rheumatoid arthritis (JRA).  
12) History of GI bleeding, or chronic GI condition that would increase risk of bleeding, 
ulceration, or perforation  
13) Hypertension.  
14) Craniofaci al syndromes.  
15) Syndrome or neurologic condition that would hinder accurate assessment of 
postoperative pain.  
16) Inability to feed orally or take oral pain medication. 
17) Chronic pain disorders , or otherwise requiring pain medication more than once weekly . 
18) Laborat ory abnormalities on the preoperative CBC:  
• Hemoglobin  < 9 gm/dL  
• Platelet count < 100,000/mm3  
19) Any investigational drug use within 30 days prior to enrollment.  
20) Pregnant or lactating females.  
21) Parents/guardians or subjects who, in the opi[INVESTIGATOR_689], may be non-
compliant with study schedules or procedures.  
22)  Hypersensitivity or allergic reactions to celecoxib, aspi[INVESTIGATOR_248], or other NSAIDs, including 
asthma flare ups 
23) Allergy to sulfonamides  or calcium carbonate.  
 
Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations 
of these criteria must be reported in accordance with IRB Policies and Procedures.  
   
   15 
4 STUDY PROCEDURES 
Please see also the Table of Procedures .  
4.1 Pre-op Phase  
• Informe d Consent  / Assent  
• Review Inclusion/Exclusion Criteria   
• Medical Record Review  
• Record data from clinical care: Demographics, Medical History, Physical Exam , 
height, weight, laboratory test (CBC with platelet count), prior/concomitant 
medications  
• Randomizati on – performed prior to surgery day. 
4.2 Study Treatment Phase (Postop day 0 un til pain -free, maximum 10 days )  
This Phase includes the day of surgery (Day 0), and the postoperative days  (maximum 10) , 
during which subjects receive study medication. 
4.2.1 Day of Surgery (Day 0)  
• Clinical Care:  Surgery and General Anesthesia, Vital Signs, Pregnancy Test, 
Medications, preoperative CBC with platelet count (if not already reviewed), give 
prescription for oxycodone and acetaminophen  
• Dispense study drug, provide instructions  
• Start study medication  
• Dispense Study D iary  
• Medical Record Review  
• This visit  including the surgery may be either at the CHOP Perioperative Complex or 
at one of the CHOP Ambulatory Surgery Centers. 
4.2.2 Telephone Call 1 (Day 3 +/ - 1) 
• Assess pain control and any problems or questions with medications or diary 
• Assess possible adverse events.  Includes specific query about the occurrence of skin 
rash and review of oral fluid intake and urine output to assess for dehydration.  
• If volume depleted, refer ral to ED.    
   
   16 
• If dehydration serious enough to require IV fluids, or elevation of serum creatinine 
as specified above, discontinue study medication.  
• Subjects reminded to call for inadequate fluid intake or urine output.  
• Assess compliance with study drug and diary  
• Medical Record Review  
4.3 Follow -up Phase (Discontinuation of study drug to Postop day 30)  
This Phase begins after the last dose of study medication.  
4.3.1 Telephone Call 2 (Day 14 +/ - 1) 
• Assess pain control and any problems or questions with medications or diary  
• Assess possible adverse events  
• Assess compliance with study drug and diary  
• Drug accountability calculation  
• Medical Record Review  
4.3.2 Telephone Call 3 (Day 30 +/ - 2) 
• Assess possible adverse events  
• Arrange return of Study D iary. 
4.4 Unscheduled Visits 
Compli cations are common during the 2- week postoperative recovery after any 
tonsillectomy, with hospi[INVESTIGATOR_356118] 5- 10% at our 
institution.    These complications include  hemorrhage, refractory pain, refractory 
nausea/vomiting, and dehydration, and will be  managed according to usual clinical care 
pathways, which include  referral to the ED as appropriate.  There are no changes in these 
pathways related to this  study.   However, the occurrence and outcomes of such visits  will 
be recorded for study purposes.  
In the event that there are problems related to study procedures that are outside the usual 
pathways  for post -tonsillectomy clinical care, subjects will be triaged by [CONTACT_356153], 
and brought into the Otolaryngology Clinic  or ED as appropriate, for evaluation by [CONTACT_356154].  
4.5 Concomitant Medications  
All prior and concomitant medications used from Days 0 -14 will be recorded. The dates of 
administration, dosage, and reason for use will be included.  
   
   17 
The foll owing concomitant medications are prohibited while receiving study drug:  
• Other NSAIDs including aspi[INVESTIGATOR_248]  
• Antiplatelet agents, anticoagulants (bleeding risk)  
• ACE inhibitors  or Angiotensin II receptor blockers  
• Antibiotics  (systemic only) :  Aminoglycosides , fluconazole , fluoroquinolones  
• CYP2D6 substrates: Aripi[INVESTIGATOR_4253], codeine  
• CYP2C8 substrates  
• CYP2C9 inducers or inhibitors  
• Corticosteroids  (systemic only)  
• Cyclosporine  
• Digoxin, Lithium, Desmopressin, Mifepristone, Nitric Oxide agents  
• Certain antihypertensives – Beta blockers, eplerenone, hydralazine  
• Chemotherapy agents: Doxorubicin  
• Hormones:  estrogen derivatives (thrombogenic enhancement)  
• Loop or  thiazide diuretics, tramadol, SSRIs, tamoxifen, prostaglandins, tenofovir  
 
4.[ADDRESS_443586] few days, until their pain becomes less intense.  The number of days are 
not specified.  Patients then switch to using both as -needed.  In this study, all subjects will 
take their acetaminophen around the clock for 5 days, with oxycodone reserved for 
breakthrough pain (but still up to every 4 hours as needed) .  After [ADDRESS_443587] this 
will be  true for study subjects as well.  These are usually managed by [CONTACT_356155], who are permitted to increase oxycodone dose up to 0.1 mg/kg/dose every [ADDRESS_443588] Completion/Withdrawal  
Subjects may withdraw from the study at any time without prejudice to their care.  They 
may also be discontinued at the discretion of the Investigator for lack of adherence to study 
treatment or visit schedules, AEs, or if it is felt by [CONTACT_356156].  Any subject who withdraws will continue to have 
appropriate pain control, since they were already prescribed standard of care analgesics.  
Postoperative hemorrhage is not rare after tonsillectomy  (typi[INVESTIGATOR_356119] 2 -5%), and so is 
expected to occur to some subjects in this study.  Subjects who experience postoperative 
   
   18 
hemorrhage will be instructed to immediately discontinue the use of study medication, in 
addition to the usual instructions for management of this complication.  However, t hese 
subjects will not be withdrawn from the study, but rather will continue in the follow -up 
phase of the study.  This includes recording pain diaries and receiving follow up calls per the 
schedule described.  This  will allow  assessment of fi nal outcomes for these subj ects, and 
maintain  the blinding needed for scientific validity of the study. 
Subjects who develop a rash while taking study medication will be instructed to immediately 
discontinue the study drug, but to continue to use their rescue medication as per clinical 
care.  As was the case for hemorrhage, these subjects will not be withdrawn from the study, 
but rather will continue in the follow -up phase of the study.  This includes recording pain 
diaries and r eceiving follow up calls per the schedule describ ed.  This will allow assessment 
of final outcomes for these subjects, and maintain  the blinding needed for scientific validity.  
As described previously  (section 3.1.2) , subjects who develop significant dehydration will 
be assessed in the ED.  Those  who require IV fluids, or have abnormalities in laboratory 
assessment ( creatinine ), immediately discontinue the study drug, but continue to use their 
rescue medication as per clinical care.  As was the case for he morrhage, these subjects will 
not be withdrawn from the study, but rather will continue in the follow -up phase of the 
study.  This includes recording pain diaries and receiving follow up calls per the schedule 
describ ed.  The study team will also follow up with the subject’s PCP to ensure  resolution of 
any abnormalities of lab values or renal function.  
The Investigator may also withdraw subjects who violate the study plan, or to protect the 
subject for reasons of safety or for administrative reasons.  It w ill be documented whether or 
not each subject completes the clinical study. If the Investigator becomes aware of any 
serious, related adverse events after the subject completes or withdraws from the study, they 
will be recorded in the source documents and on the CRF.  
4.7.[ADDRESS_443589] prior to screening , operative notes from the tonsillectomy procedure, 
and perioperative nurs ing and anesthesia notes: Date of birth, date of surgery, operating 
surgeon.  Height, weight. Other comorbid medical conditions.  Prior/concomitant 
medications. Prior surgical procedures.  Diagnosis necessitating surgery (e.g. sleep -
disordered breathing, c hronic tonsillitis).  Data from preoperative polysomnogram, if 
performed.  Tonsil size from operative note .  Surgical details (method of tonsil removal, 
cautery wattage/mode, complications, procedure time).  Analgesics given during procedure 
and in PACU, including doses.  Corticosteroids and their doses given intraoperatively . 
   
   19 
4.8.2 Laboratory Evaluations  
Values are recorded from certain  laboratory studies done routinely for clinical care.  These 
are listed below.  There are no research -only laboratory studies.  
[IP_ADDRESS] Hematology Tests  
As part of clinical care, all patients without a recent hemoglobin and pl atelet count (within 
the prior 6 months) undergo a preoperative blood draw (CBC with platelet count).  Results 
are recorded for this study.  If any preoperative coagulation studies are performed for 
clinical care, these data are also recorded.      
[IP_ADDRESS] Pregnancy Testing  
As part of clinical care prior to administering general anesthesia,  a urine pregnancy test is 
always perfo rmed for female subjects ≥  11 years of age and girls <[ADDRESS_443590] is 
positive, subjects will be withdrawn from the study.  
4.9 Efficacy Evaluations 
4.9.1 Days receiving na rcotic medication  
Following Sobol et al [2006], the day a subject is considered “off” narcotic medication is 
defined as the day they received either 0 or only 1 dose of narcotic.  This number is recorded 
from the number of doses of oxycodone subjects recor d each day in the ir Study Diary.  
4.9.2 Pain Scales  (See Appendix)  
The subject’s pain level is recorded on the study Diary in the recovery room, then twice 
daily , just before receiving each  dose of study medication.  The 10- point Wong- Baker 
FACES pain scale is used for all ages (scale is validated for ages 3 and above)  [Wong and 
Baker 1988].  Alternatively, children [ADDRESS_443591] commonly oxycodone suspension 0.075 mg/kg/dose every 4 hours as needed, 
and acetaminophen syrup 15 mg/kg/dose every [ADDRESS_443592] 5 days.  Quantity  administered in the PACU is recorded from flowsheets.  Initial 
volume received from the pharmacy, and drug concentration, are r ecorded.   Volumes of 
each dose given at home (in increments of 0.1 mL) are recorded by [CONTACT_356157].   
At the end of the two week postoperative period, during T elephone Call #2, caregivers will 
measure the remaining volume of unused oxycodone and acetaminophen, to the nearest 1 
mL, using an appropriate syringe (e.g. 20 cc) given to them on the surgery day.   
   
   [ADDRESS_443593] whether their diet was predominantly liquid 
diet, soft diet, or normal diet that day.  
4.9.5 Data Collection from Hospi[INVESTIGATOR_356120] . Medical records are reviewed 
from each hospi[INVESTIGATOR_21186] (Emergency Department, Emergency Dept. Extended Care Unit, or 
inpatient records): date, reason for readmission, diagnosis, laboratory studies, medications 
administered (analgesics, antiemetics, steroids, antibiotics), and other treatm ent 
administered (intravenous fluids, oral fluids, surgical reoperation, observation for bleeding).  
4.[ADDRESS_443594] safety will be monitored by [CONTACT_20721], which include the serious adverse event  
of postoperative hemorrhage.  The PI [INVESTIGATOR_356121] S AEs immediately, and other AEs e very 2 
weeks with the study team.  As described in section 5.2.4 above, data is collected for all 
hospi[INVESTIGATOR_356122] 30 days following surgery, and this includes the AE data listed 
in that section.   Further details are in Section 8 below.  
 
   
   21 
5 STATISTICAL CONSIDER ATIONS 
5.1 Primary Endpoint  
The primary endpoints are (1) number of days on narcotic medication, and (2) total amount  
of rescue narcotic pain medication consumed.   
5.2 Secondary Endpoints 
Secondary endpoints w ill include the following:  
• Efficacy based on t ime to return to normal diet, quantity of rescue acetaminophen used, 
and rate of readmission for dehydration or excessive pain.   
• Safety based on  rates of postoperative hemorrhage. 
• Safety and tolerability of celecoxib based on Adverse Events.  
 
5.[ADDRESS_443595] descriptive 
summaries (e.g. means and standard deviations for continuous variables such as age and 
percentages for  categorical variables such as gender).  
5.3.2 Efficacy Analysis  
The primary analysis will be based on an intention to treat approach and will inc lude all 
subjects who are randomized .   
The primary efficacy endpoint will be (1) the difference in number of days on narcotic 
medication, and (2) the difference in total amount  of rescue narcotic pain medication 
consumed in the 2- week postop period.  For the latter, total amount of oxycodone consumed 
will be expressed as morphine equivalents per kg body weight. 
Secondar y efficacy endpoints will include the difference in t ime to return to normal diet, 
difference in amount  of rescue acetaminophen used, and difference in rate of readmission 
for dehydration or excessive pain.   
The above efficacy variables will be compared between the two treatment groups by a two -
sample t -test. 
Note:  Statistical analysis is the same for all subjects, regardless of whether or not they 
became pain -free and discontinued study drug before the maximum10 days of dosing. 
Subjects who miss more than [ADDRESS_443596] 5 days, 
will not be included in the efficacy analysis.  These subjects continue their study medication 
per protocol, but their efficacy data will be analyzed separately at the end of the study.  All 
will continue to be included in the safety analysis.  
   
   22 
5.3.3 Safety Analysis  
All subjects entered into the study at the preoperative visit will be included in the safety 
analysis. The frequencies of AEs by [CONTACT_24975], body system, severity and relationship to study 
drug will be summarized. SAEs (if any) will be described in detail.   The frequency of 
postoperative hemorrhage will be summarized.  
Postoperative hemorrhage and AE incidence will be summarized along with the 
corresponding exact bin omial 95% two -sided confidence intervals.  
5.[ADDRESS_443597] udy done at CHOP  (referred to below as the M icrodebrider study) [ Sobol et al 2006] .  
Sample size estimates were made separately for both primary efficacy endpoints, based on 
the available data .  This was done with t wo-sample power analysis based on average values, 
using an alpha of 0.05 and beta 80%.  If variance  for the experimental group was  not 
available, an assumption of equal variance  as the control group was made. 
We determined the sample size needed to detect the foll owing meaningful differences:  a  
reduction of 1 day in number of days on narcotic medication, as recommended in Sobol et al 
[2006], and a reduction of 20% in total narcotic consumed.  
Days on narcotic pain medication:  The CHOP M icrodebrider s tudy reported that children in 
their control group required narcotic medication a mean 8.2 days (SD  2.7 days ).  These 
children underwent standard electrocautery tonsillectomy, and so were essentially  identical 
to our placebo control group.  Based on these results and as suming equal  variance in both 
groups , a sample size of [ADDRESS_443598]  a 1-day improvement  in this 
outcome variable.  
Total  narcotic pain medication consumed :  The University of Iowa pi[INVESTIGATOR_799] [ Van Daele et 
al 2014] reported rescue narcotic consumption in a small group of adults randomized to 
either celecoxib or placebo.  Narcotic equivalents were consumed as follows: 632 (381) in 
placebo group; 262 (148) in celecoxib group.  Based on these results, a sample size of [ADDRESS_443599]  a 20%  improvement  in this outcome variable.  
We expect a  dropout ra te of up to 40%, mainly from  subjects who  never return their Study 
Diary, or who do so without accurately recording total narcotic consumed.  This  estimate is 
based on our expe rience with diary returns  in prior tonsillectomy studies, which are lower 
than other trials because of the fact there is no routine post -operative  clinic visit after routine 
tonsillectomy surgery.  Based on this rate, a final sample size estimate of 150 per group is 
needed to yield the 90 per group needed to assess our  primary endpoints.  
5.5 Interim Safety Analysis 
No interim analysis for efficacy will be performed in this study.  However, an interim 
analysis for safety may be performed under certain conditions  described below.  
   
   23 
As noted previously, postoperative hemorrhage is not rare after tonsillectomy ( typi[INVESTIGATOR_356119] 
2-5%), and so is expected to occur in 6 to 14 children over the entire study .  We anticipate 
similar hemorrhage rates between the two groups, so up to 7 children per group. As noted 
earlier, these  subjects discontinue study drug and undergo clinical care, but remain blinded 
and continue on the study to undergo  monitoring procedures .   
Even though blinded, the  PI [INVESTIGATOR_356123].  An interim safety analysis (with unblinding) will  then be performed in 
either of the following  cases:  
• If, after the first 50 subjects are treated  in either group, greater than 5 children 
experienced significant hemorrhage in that group, OR  
• If at any point in the study, the PI [INVESTIGATOR_356124] a concerning 
difference in bleeding rate between the 2 groups . 
The study would then be stopped if the unblinding then revealed  both that the higher rate 
occurred in the celecoxib group, and that the hemorrhage event s were  probably or definitely 
related to the study drug.    
 
 
   
   24 
6 STUDY MEDICATION   
6.1 Description 
The study drug is celecoxib (Celebrex, [COMPANY_007] , or generic equivalent ).  Celecoxib  is a 
nonsteroidal anti -inflammatory drug that exhibits anti -inflammatory, analgesic, and 
antipyretic activities. The mechanism of action is believed to be due to inhibition of 
prostaglandin synthesis, primarily via inhibition of cyclooxygenase -2 (COX- 2), and at 
therapeutic concentrations in humans, celecoxib  does not inhibit the cyclooxygenase -1 
(COX- 1) isoenzyme.  
Suspension formulations :  While a suspension of celecoxib is still not commercially 
available, several investigational suspensions have been studied.  The FDA reviewed [COMPANY_007] 
RR-754-[ZIP_CODE] reporting pharmacokinetic study of celecoxib suspension (Study 195), which 
included suspensions of 50 mg/5mL and 100 mg/5 mL in 242 children at 60 sites.  Of these, 
202 went on to open- label use of the suspensions at 3 mg/kg BID.  [FDA,  BCPA Summary 
for NDA 20 -998, Supplement  021].   In a published study, PK and efficacy were studied in 
children with JRA using an investigational suspension, in 152 JRA patients aged 2 to 17 
years [Krishnaswami et al 2012].  The Children’s Hospi[INVESTIGATOR_356125] 10 mg/mL suspension in Ora -Blend [Donnelly et al,  2009].   This suspension is stable 
for at least 90 days, either at room temperature or refrigerated.  This suspension was used 
safely in thei r recent large clinical trial in pediatric tonsillectomy [Murto et al 2015].  
For this study, bulk drug will be obtained by [CONTACT_356158] 100 mg/5 mL (20 mg/mL) in Ora -Blend or 
equivalent , following Donnelly et al [2009].   
Placebo, with appearance, taste and consistency as similar  as possible to the active drug, will 
be mixed in identical fashion.   P lacebo  consists of calcium carbonate powder suspended in 
the same syrup as the active drug.  The dose of elemental calcium is 3 mg/kg/day.  Calcium 
carbonate in this concentration provides a cloudy appearance identical to celecoxib 
suspension, with no characteristic taste.  
6.1.[ADDRESS_443600] is enough to supply a total 20 doses.  
6.1.2 Labeling  
Labeled by [CONTACT_356159].  
6.1.3 Dosing  
Dosing of celecoxib is 6 mg/kg BID, maximum [ADDRESS_443601] under the terms and conditions set forth in this 
protocol.  The study medication is to be pres cribed by [CONTACT_356160].  
   
   26 
7 SAFETY MANAGEMENT  
7.1 Clinical Adverse Events 
Clinical adverse events (AEs) will be monitored throughout the study.  The procedures for 
obtaining this information (via phone interview, recording of data from unscheduled 
admissions, and study diaries) were described in Section 5.1, with the schedule in Table 1.  
7.2 Adverse Event Reporting  
Unanticipated  problems related to th e research involving risks to subjects or others that 
occur during the course of this study (including SAEs) will be reported to the IRB in 
accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. 
AEs that are not serious but t hat are notable and could involve risks to subjects will be 
summarized in narrative or other format and submitted to the IRB at the time of continuing 
review.  
7.[ADDRESS_443602] who has received the 
study drug (celecoxib or placebo ).  The occurrence does not necessarily have to have a 
causal relationship with the treatment.  An AE can therefore be any unfavorable or 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.  
All AEs (including serious AEs) will be noted in the study records and on the case report 
form with a full de scription including the nature, date and time of onset, determination of 
non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and 
outcome of the event.  
7.4 Definition of a Serious Adverse Event (SAE)  
An SAE is any adverse drug e xperience occurring at any dose that results in any of the 
following outcomes:  
• death,  
• a life -threatening event (at risk of death at the time of the event),  
• requires inpatient hospi[INVESTIGATOR_1081], 
• a persistent or si gnificant disability/incapacity, or  
• a congenital anomaly/birth defect in the offspring of a subject.   
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug event whe n, based upon 
appropriate medical judgment, they may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. 
   
   27 
A distinction should be drawn between serious and severe AEs.  A severe A E is a major 
event of its type.  A severe AE does not necessarily need to be considered serious.  For 
example, nausea which persists for several hours may be considered severe nausea, but 
would not be an SAE.  On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke, but would be an SAE.  
7.4.1 Relationship of SAE to study drug or other intervention 
The relationship of each SAE to the study drug should be characterized using one of the 
following terms in acco rdance with CHOP IRB Guidelines: definitely, probably, possibly, 
unlikely or unrelated.  
7.5 Anticipated SAEs  
The following are the known S AEs related to surgery that are anticipated  based on current 
clinical experience , and the approximate rates that are expe cted.   These SAEs will be  
recorded and their rates monitored carefully, but are  reported differently to the IRB from the 
unanticipated SAEs, as discussed in Section 8.6 below. 
1. Postope rative h emorrhage  (expected rate up to 10%) 
Hemorrhage is not rare  after tonsillectomy , and so is anticipated in both treatment 
groups.  Rates are typi[INVESTIGATOR_897] 2 -5%, but rates  up to 10% have been observed in some 
months at CHOP .  Hemorrhage is always considered a life- threatening SAE.  We 
further anticipate that rates of the  two groups will be similar.  Hemorrhage events, 
including hospi[INVESTIGATOR_262267], will be recorded, and their rates 
and outcomes monitored by [CONTACT_978] [INVESTIGATOR_16817].  
2. Postoperative rea dmission  (expected rate up to 10%).  
From  internal quality monitoring data  over the last  2 years, rates of readmission of 
up to 10% have been observed.  Historically these result from hemorrhage (described 
separately above) , pain -related complications (uncontrolled pain, dehydration ), and 
side effects from  narcotics or anesthesia (e.g., nausea,  vomiting). 
3. Prolonged initial admission (expected rate up to 30%  of those kept overnight ).   
Children who are admitted overnight after surgery often stay hospi[INVESTIGATOR_057] a second 
night or longer.  The most common reason is inadequate oral intake, which is most 
common in the younger children.   Other reasons include inadequate pain control, the 
need for more time to wean off supplemental oxygen, or the need for an additional 
night of respi[INVESTIGATOR_356126].  
 
 
   
   28 
7.6 IRB/IEC Notification of SAEs  and Other Unanticipated Problems 
The Investigator will promptly notify the IRB of all unanticipated, serious Adverse Events 
that are related to the research activity. Other unanticipated problems related to the research 
involving risk to subjects or others will also be reported promptly. Written reports w ill be 
filed using the eIRB system and in accordance with the timeline below.   
Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Death or Life Threatening 
SAEs  (not listed in Section 
8.5)*   24 hours  Within 2 calendar days  
All other SAEs   
(not listed in Section 8.5)*  7 days  Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of important 
AEs may be reported at time 
of continuing review  
 
*For the Anticipated SAEs  listed in Section 8.5 above, the Investigator will report these 
events differently than other SAEs.  If rates of Anticipated SAEs  fall within the expected 
ranges listed in Section 8.5, they will be reported similarly to AEs, as a summary at the time 
of Continuing Review.  However, if their rates exceed the expected ranges, they will be 
reported promptly to the IRB  as per the above t able (i.e., 24 hours for life threatening SAEs, 
7 days for all other SAEs).  Death will always be reported within 24 hours regardless of the 
circumstances.  
7.6.1 Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that 
changes the investigator’s assessment of the event, a follow -up report including all relevant 
new or reassessed information (e.g., concomitant medication, medical history) should be 
submitted to the IRB. The investigator is responsible for ensuri ng that all SAE are followed 
until either resolved or stable.  
7.7 Investigator Reporting of Serious Adverse Events to Funder  
Reporting of S AEs will be consistent with funder requirements ( Safety Reporting Reference 
Manual for IIR Studies with [COMPANY_007] Products ).  Subjects are identified only by [CONTACT_356161].  
7.8 Medical Emergencies 
On the day of surgery, initial study procedures occur  within the perioperative complex at 
CHOP  or a CHOP ambulatory surgery center .  Any m edical or  surgical emergencies at that 
   
   29 
time a re handled in the usual fashion by [CONTACT_356162].  
Postoperatively, som e patients are discharged (Day S urgery) while others are  admitted 
overnight for observation, as per clinical care.  For the latter , any emergencies during the 
admission are handled by [CONTACT_356163].  During the home recovery 
period for all subjects , medical emergencies common  during the postoperative period (for 
example, dehydration and hemorrhage) are managed in the same way a s outside the 
research, per well -established protocols.   Any unusual  emergencies besides those 
occurrences are not expected, but if they occur, each will be assessed by [CONTACT_356164], or the physician on call after hours, with subjects directed to the 
Emergency Department as needed.  
   
   [ADDRESS_443603]’s cur rent medications.   The most notable example of such a 
situation is hemorrhage.   All patients who experience hemorrhage immediately stop their 
study drug, whether active or placebo, and then subsequent clinical management is the same 
regardless of which g roup they were assigned.  
8.[ADDRESS_443604] data specified.  Data is logged into REDCap kept on encrypted 
hospi[INVESTIGATOR_307] -issued computers.   Data will be managed and stored using the research -focused 
electronic data capture system REDCap, under an agreement with the software’s 
development consortium, led by [CONTACT_50222]. REDCap supports two secure, web-
based applications designed exclusively to support data capture for research studies.  
REDCap as implemented at CHOP includes daily destructive database backup files that are 
stored on the database server and are deleted only after successful backup of the entire 
database to file.  Data and backups are stored in the CHOP Research Information Systems 
Storage Area Network (SAN).  Access to the SAN directories where data are stored will be 
limited to Research Information Systems personnel, with authentication performed using 
CHOP’s enterpri se Active Directory service.  
Data are recorded either directly into REDCap, or initially on paper forms then transferred to 
REDCap in a timely fashion, then the paper forms destroyed.  The datasheets and REDCap 
database will contain only coded information.  Only limited datasets will be exported from 
   
   [ADDRESS_443605] privacy. The Investigators and other personnel 
will not use such data and records for any purpose other than conducting the study, unless 
the IRB approves (or exempts) other uses. Safeguards are described under Data Collection 
and Management .  If any investigator leaves the institution he or she will surrender any 
identifiable data.  It is expected that publications or presentations will include only 
aggregate data.   
Confidentiality will be maintained by [CONTACT_61604], which assigns each subject wi th a Subject 
ID and keeps identifying information separate from the data.   Once data is collected, the 
PHI will be accessed only in the event, prior to publication, that the charts need to be 
accessed a second time.  This would occur if only if questions arise from reviewers or 
regulatory agencies  that were not recorded duri ng the original data collection.   Thus, 
maximum privacy of patient identifying information is ensured, while at the same time 
maintaining a secure link necessitated by [CONTACT_356165]. 
During the data collection process, the temporary paper data collection forms, charts and 
other records will not leave the CHOP premises, and will be kept in a locked office.  Access 
will be limited only to the study tea m members .   Digital data will be accessed only using 
CHOP hospi[INVESTIGATOR_356127].  
8.[ADDRESS_443606] of its adverse 
effects being  associated with chronic, long term use , or with use in certain conditions not 
applicable to children or to the current study (e.g., cardiovascular thrombotic disease) .  
Importantly,  essentially all of the risks described below are not unique to celecoxib, but 
rather apply to all NSAIDs.  Of course, other NSAIDs are already used extensively in 
children of all ages , especially for short term therapy, including postoperative pain control.  
Below, we first discuss risks most applicable to short -term administration in this study, 
followed by [CONTACT_356166] -term treatment .  Each  is followed 
by [CONTACT_356167].  The risk discuss ions are based on 
information  from the manufacturer ( [COMPANY_007] Celebrex Full Prescribing Information 
document ).  
Risks applicable to short -term therapy  
Aspi[INVESTIGATOR_248] -Sensitive Asthma -- All NSAIDs  may precipi[INVESTIGATOR_356128].  It is well known that a spi[INVESTIGATOR_356129] -sensitive asthma, which  can be fatal. Since cross reactivity between 
aspi[INVESTIGATOR_356130] n reported in such aspi[INVESTIGATOR_248]- sensitive patients, celecoxib 
could cause this event in patients with this form of aspi[INVESTIGATOR_79948].  More generally, the 
manufacturer recommends using celecoxib with caution in patients with preexisting asthma.   
This risk is  minimized in the present study by [CONTACT_356168][INVESTIGATOR_248] -sensitive 
asthma, any prior severe reactions to aspi[INVESTIGATOR_49267] , or any form of moderate to severe 
asthma, even in the absence of known aspi[INVESTIGATOR_79948].  
Anaphylactic  Reactions -- As  with all NSAIDs in general, rare anaphylactoid reactions have 
occurred  in patients, even without known prior ex posures . In post -marketing experience 
reported by [CONTACT_3455] , rare cases of anaphylactic  reactions and angioedema have 
been reported in pa tients receiving celecoxib . This risk is minimized in the present study by 
[CONTACT_356169][INVESTIGATOR_49267]. 
Skin Reactions -- Celecoxib is  a sulfonamide and can cause rare but serious skin reactions  
such as exfoliative derm atitis , Stevens -Johnson syndrome , and toxic epi[INVESTIGATOR_194] , 
which can be fatal.  These serious events can occur without  warning and in patients without 
prior known sulfa allergy .  This risk is minimized in the present study by [CONTACT_356170], and subjects are informed about the signs and symptoms  of 
serious skin manifestations and counseled to stop the study drug at the first appearance of 
skin rash or any other sign of hypersensitivity.  
   
   33 
Postoperative Hemorrhage  -- As described in earlier sections, use of celecoxib does not 
appear to increase bleeding risk after surgical procedures.  On the contrary , Cox -2 inhibitors  
actually reduce the amount of blood l oss during orthopedic procedures [Li et al 2009] .  
Preliminary data after tonsillectomy (discussed above) suggests that bleeding risk is not 
increased for this surgery either.  Nevertheless, since no large studies have yet been 
performed, the effects of celecoxib on bleeding risk after tonsillectomy must be considered 
unknown at this time .  Of course, our hypothesis is that celecoxib will actually reduce 
bleeding risk, due to its absence of platelet inhibition. This risk is minimized in the present 
study by (1) the nature of celecoxib as a selective COX -2 inhibitor; (2) excluding subjects 
with coagulation disorders, and (3) by [CONTACT_356171] S AE as described 
in this protocol.  
Other side effects reported in clinical trials:  
Adults  – the following side effects occurred at a rate greater than placebo, and in >2% of 
adults, in the pre-marketing controll ed arthritis trials.  Notably, all of these were the same or 
less than  for the other NSAIDs in the trial (naproxen, diclofenac, ibuprofe n): 
Gastrointestinal  
Abdominal Pain 
Diarrhea  
Dyspepsia  
Flatulence  
Body as a whole  
Peripheral Edema  
Respi[INVESTIGATOR_356131] /Sinusitis  
 
Children  -- Below (Table 3) are the AEs reported  during chronic long term use in children 
for JRA, as reported  by [CONTACT_3455] .  The s ide effect profile appears very similar to 
naproxen, another NSAID. 
 
Table 3. Adverse events occurring in >5% of JRA patients in any 
treatment group, by [CONTACT_9313] (% of patients with events)  
 
System Orga n 
Class  
Preferre d Term  Celecoxib 3 
mg/kg BID  
 N=77 Celecoxib 6  
mg/kg BID  
 N=82 Naproxen 7.5 
mg/kg BID  
 N=83 
Any Event 64 70 72 
Eye Disorders  5 5 5 
Gastrointestinal  26 24 36 
Abdomina l pain NOS 4 7 7 
Abdomina l pain upper 8 6 10 
Vomitin g NOS 3 6 11 
Diarrhe a NOS 5 4 8 
Nausea  7 4 11 
General  13 11 18 
Pyrexia  8 9 11 
Infections  25 20 27 
Nasopharyngitis  5 6 5 
Injury  and Poisoning  4 6 5 
Investigations*  3 11 7 
   
   34 
Musculoskeletal  8 10 17 
Arthralgia  3 7 4 
Nervous S ystem 17 11 21 
Headach e NOS 13 10 16 
Dizzines s (excl vertigo)  1 1 7 
Respi[INVESTIGATOR_696]  8 15 15 
Cough  7 7 8 
Skin & Subcutaneous  10 7 18 
*Abnormal laboratory tests, which include: Prolonged activated partial thromboplastin 
time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture 
positive, Blood glucose increased, Blood pressure increased, Blood uric acid increased, 
Hematocrit decreased, Hematuria present, Hemoglobin decreased, Liver function tests 
NOS abnormal, Proteinuria present, Transaminase NOS increased, Urine analysis 
abnorm al NOS . 
Risks unlikely in short term use in pediatric subjects:  
Cardiovascular effects --NSAIDs now carry a Boxed Warning regarding this risk.   All 
NSAIDs are associated with increased risk of serious adverse cardiovascular thrombotic 
events, including myocardial  infarction and stroke. These r isks are increased with long term 
use and pre -existing cardiovascular disease or risk factors.  Celecoxib is believed to be 
similar to all the  other NSAIDs regarding this risk.  Likewise, a ll NSAIDs, including 
celecox ib, also  can lead to the onset of new hypertension or worsening of preexisting 
hypertension, and may cause fluid retention or ede ma in the setting of congestive heart 
failure .  None of these events or effects have been reported in children.  
These risk s are essentially nonexistent  in our subjects, who are children, and who are 
receiving very short term therapy.  Risk is further minimized by [CONTACT_356172].  
Serious GI events  – All NSAIDs, including celec oxib, can cause serious gastrointestinal 
events including bleeding, ulceration, and perforation of the stomach, small intestine or large 
intestine, which can be fatal.  NSAIDs now carry a Boxed Warning regarding this risk.   
These events were reported duri ng chronic use in adults, where the overall rate of 
complicated and symptomatic ulcer rates was reported as 0.78% (CLASS trial).  Higher 
rates were found in adults with risk factors, including prior history of peptic ulcer disease 
and/or gastrointestinal b leeding (10- fold increased risk), concomitant use of oral 
corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of 
alcohol, older age, and poor general health status.  
These risks are exceedingly small in our subjects, who are children and receiving very short 
term therapy.  Risk is further minimized by [CONTACT_356173], or chronic GI condition that would increase risk of bleeding, ulceration, or 
perforation, and presence of other risk factors for  GI bleeding  (aspi[INVESTIGATOR_248], other anticoagulants, 
chronic steroids ).   
Effects on Renal Function – all NSAIDs may compromise renal function, and should be 
avoided  in patients  with impaired renal function.  Clinical trials show celecoxib is no 
different from the other NSAIDs . This risk is minimized in the present study by [CONTACT_356174] a history of  renal disease.  
   
   35 
Volume depletion may increase the chance of renal injury from  NSAIDs [ Misurac 2013 ].  
However, some  authors  have not found such an association with short term NSAID use 
[Lesko, 1997] .  Subjects undergoing tonsillectomy may experience dehydration due to 
inadequate pain control, with rates of readmission for dehydration observed from 1 -5% at 
CHOP.  This r isk is minimized in the present study as follows:  
1. Excluding any subjects with pre -existing renal disease.  
2. Subjects’ self -monitoring of  intake and urine output to ensure early detection of 
dehydration, as described in section 3.1.2. 
3. Nurse call on Day [ADDRESS_443607] pathways.  
5. Discontinuation of study drug if  dehydration is serious enough to require intravenous 
fluids, or if abnormal renal function is observed (elevated creatinine) . 
6. Better pain control in the NSAID group -- w e expect subjects in the celecoxib group 
will have better  pain control, and thus less risk of dehydration, than placebo subjects 
or children outside the research.  
Effects on Hepatic function --  Borderline elevations of one or more liver -associated 
enzymes may occur in up to 15% of patients taking NSAIDs, and “ notable ” elevations of 
ALT or AST (approximately 3 or more times the upper limit of normal) have been reported 
in approximately 1%  of patients in clinical trials with NSAIDs.  For celecoxib specifically, 
the incidence was lower, in fact similar to placebo ( borderline elevation of 6% for celecoxib  
and 5% for placebo, and “notable” elevations in only  0.2% taking celecoxib  and 0.3% taking 
placebo ).  These risks are exceedingly small in our subjects, who are children on very short 
term therapy.  Risk is further minimized by [CONTACT_356175] a history of  hepatic 
disease.  
Coagulation effects in Systemic O nset JIA/JRA:   The preclinical JRA studies found that 
children  with systemic onset JRA (without active systemic features) were  at risk for the 
development of abnormal coagulation laboratory tests.  This risk is minimized in the present 
study by [CONTACT_356176] .  
Anemia  -- Anemia was observed in chronic celecoxib trials at a slightly higher rate than 
placebo (0.6% vs 0.4%).  This ri sk is minimized in the present study by [CONTACT_356177] (Hgb <9 g/dL) . 
Minimizing  Risks  of Celecoxib in this Study 
Risks of study medication are minimized as noted above under  each risk category.  They are 
also minimized by [CONTACT_356178]:  
• Dosing has been used safely in both children and adults.  Further, the same dosing 
was used safely in children for up to 24 weeks [Foeldvari 2009], whereas in the 
present study dosing is only short term (10 days) . 
• The exclusion criteria  minimize risk by [CONTACT_356179], as noted above.  
• Adverse events are closely monitored by [CONTACT_32816] [INVESTIGATOR_356132]. 
   
   36 
 
2. Risk Assessment: Placebo administration  
The risk level in the placebo  group is minimal, since these subjects essentially undergo the 
same management as would occur outside the research.   Pain levels will be the same as 
current standard of care, as is bleeding risk.  Pain is mitigated by [CONTACT_356180], which is the same as outside the research.  All subjects receive  the same dose 
and quantity of oxycodone/acetaminophen as those currently given to children in clinical 
care.  As in clinical care, placebo subjects receive around- the-clock dosing of 
acetaminophen, but instead of doing so for an unspecified duration, it will be specified as the 
first [ADDRESS_443608] 5 days.   
The placebo excipi[INVESTIGATOR_841] (calcium carbonate) is a ubiquitous dietary calcium supplement and 
mild antacid (e.g., Tums).  The dose used in this study ( elemental calcium dose of 3 
mg/kg/day)  is far lower t han therapeutic dosing required for any indication (range 50 -150 
mg/kg/day) .  Allergy to calcium carbonate is rare, and children with such an allergy are 
excluded at the time of screening.  
3. Risk s of other study procedures  
Risks associated with interviews and Study Diary are m inimal.  There is risk of temporary 
embarrassment on answering medi cal questions during interviews. 
8.4.[ADDRESS_443609] already completed their clinical evaluation by [CONTACT_356181], and the dec ision for surgery (tonsillectomy with or without 
adenoidectomy) will have already been made.  During the same visit, the pre -operative nurse 
practitioner  (NP)  history and physical will have already been performed as part of standard 
clinical care.  This NP  will notify the study staff of the potential subject.  At this point, a 
member of the study staff will approach potentially eligible subjects to explain the study and 
determine if the family is interested in enrolling.  Interested families then proceed wi th the 
remainder of the procedures listed under Screening Visit, above.  Informed consent is then 
obtained as per the next section.  This pre -operative clinic vi sit is anywhere from [ADDRESS_443610] typi[INVESTIGATOR_897] 2- 6 weeks p rior to the procedure date.  
It is possible some potential subjects will be interested in the study, but will be unable to 
complete screening procedures on the same day as the preoperative clinic visit.  An example 
might be subjects recruited from clinic vi sits at the CHOP Specialty Care Centers, where a 
Study Team Member is not immediately available.  These subjects will be given a  blank 
consent document , with instructions to read it at home.  They  will receive a telephone call 
from a member of the Study Team within the next few days.  The Team member will 
explain the research study in detail, answer any questions, and perform screening procedures 
as indicated above.  A time will then be arranged to  perform the Informed Consent process 
below, electronically or in person, before the scheduled surgery.  
8.6 Informed Consent/Assent  and HIPAA Authorization  
At the end of  the pre -operative clinic visit, a member of the study staff screens interested 
patients  and reviews inclusion and exclusion criteria as described in the Screening Visit 
section.  The study and its risks are explained to the subject and family and informed 
consent (and assent, if applicable) is obtained.  An otolaryngology physician will be 
immediately available to answer any questions about the study procedures or risks. The 
family is then given a copy of  the Informed Consent document at the end of the visit .  This 
document is a combined consent /assent  and HIPAA authorization.  These discussion s occur 
in a private room in the outpatient clinic.  
For the subjects described in Section 8.5, who were unable to perform the Informed Consent 
process at the clinic visit, the following will occur.  A Study Team member will telephone 
the potential subject well ahead of the surgery day, explain the study to them, and perform 
screening assessments as described above.  The actual Informed Consent/Assent process 
will occur as follows.  For those subjects who are scheduled for any visit to Main Campus 
prior to the surgery date, consent/assent will simply be obtained in person at that visit .  An 
otolaryngology physician will be immediately available by [CONTACT_356182].  The family is then given a copy of  the 
Informed Consent document at t he end of that  visit.  
For the remaining subjects not coming to Main Campus prior to surgery, an electronic / 
remote written consent process will be implemented , following FDA guidelines .  For  any 
subject who does not yet have the consent form, or lost it,  it will first be sent to them  by 
[CONTACT_6972], e -mail, or mail .  The  consent interview is  then conducted by [CONTACT_356183] 
   
   38 
parent  can read the consent form during the discussion (and when the child is available for 
assent, if applicable) . After the consent discussion, the parent (and child, if applicable) will 
sign and date the consent form  and return the entire consent form  to us by [CONTACT_6972], by 
[CONTACT_356184] a secure e- mail acco unt, or by [CONTACT_2319].  This team member obtaining 
consent will document in REDCap that the person signing the document is the subject /parent  
who will be participating in the research.  The parent  will have the opportunity to ask 
questions and receive answers pr ior to signing the form.   A n otolaryngology physician will 
either be  immediately available during the call to answer any questions about the study 
procedures or risks , or the parent  will be given a description of how and when they will 
receive answers to their questions (usually by a telephone call later from the physician) .  The 
family keeps their copy of  the signed Informed Consent document.  Upon receipt, the team 
member who obtained the remote consent will then file the complete document, after first 
signing and dating the signature [CONTACT_1787].   If the child is [ADDRESS_443611] of care outside the study, and that they will still obtain the recommende d surgery in 
the usual fashion.  Families are given as much time as they need to make their decision and 
ask questions of the staff and physician, who will ensure that subjects comprehend the 
nature of the study, the study procedures and the risks and bene fits of participation  before 
providing consent.  
8.7 Payment to Subjects/Families 
8.7.1 Reimbursement for travel, parking and meals  
Not applicable.  There are no study visits separate  from clinical care . 
8.7.2 Payments to parent for time and inconvenience (i.e. compensation)  
Parents who complete all study procedur es and return their Study Diary will receive a 
$25.[ADDRESS_443612] found poor compliance rates with comple ting/ returning 
diaries when no incentive is offered.  This is especially important in this study design, since 
subjects do not routinely return for any visits postoperatively, and must complete these 
materials at home, and mail them back to us.   This is an inconvenience to parents, who must 
perform extra work at home (completing Diaries, measuring pain, logging doses of pain 
medication, and mailing the Diary back) during an often difficult and painful postoperative 
recovery period. 
8.7.[ADDRESS_443613] for time, effort and inconvenience (i.e. compensation)  
No payment to subjects themselves.   Because the side effects of study drug are expected to 
be minimal,  the hardship, effort, and inconvenience for the pediatric subjects are similar as 
outside the research.  
   
   39 
8.7.4 Gifts  
Not applicable.  
9 PUBLICATION 
Results of this research will be presented at national meetings  and will be published in 
relevant journals.  Appropriate disclosure will be made that the research was conducted 
under off -label use of the study medicatio n. 
 
10 REFERENCES  
Baugh RF, Archer SM, Mitchell RB, Rosenfeld RM, Amin R, Burns JJ, Darrow DH, 
Giordano T, Litman RS, Li KK, Mannix ME, Schwartz RH, Setzen G, Wald ER, Wall 
E, Sandberg G, Patel MM.  Clinical practice guideline: tonsillectomy in children. 
Otolaryngol Head Neck Surg. 2011;144:S1- 30. 
Cardwell ME, Siviter G, Smith AF.  Non -steroidal anti -inflammatory drugs and 
perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev. 
2005;(2):CD003591. 
Derry S, Moore R. Single dose oral celec oxib for acute postoperative pain in adults. 
Cochrane Database Syst Rev 2013;10:CD004233. 
Donnelly RF, Pascuet E, Ma C, Vaillancourt R. Stability of celecoxib oral suspension. Can J 
Hosp Pharm. 2009;62:464- 8. 
Foeldvari I, Szer I, Zemel L, et al. A Prospect ive Study Comparing Celecoxib with 
Naproxen in Children with Juvenile Rheumatoid Arthritis. J Rheumatol 2009;36:174 -
182. 
Hippi[INVESTIGATOR_356133] -Cox J, Coupland C, Logan R.  Risk of adverse gastrointestinal outcomes in patients 
taking cyclo -oxygenase -2 inhibitors or conventional non- steroidal anti -inflammatory 
drugs: population based nested case -control analysis.  BMJ 2005; 331:1310- 1316. 
Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N. An evaluation of the safety 
and efficacy of administering rofecoxib for post operative pain management. Anesth 
Analg. 2003;97:35- 8. 
Krishna S, Hughes LF, Lin SY.  Postoperative hemorrhage with nonsteroidal anti -
inflammatory drug use after tonsillectomy: a meta -analysis. Arch Otolaryngol Head 
Neck Surg. 2003;129:1086- 1089. 
Krishnasw ami S1, Hutmacher MM, Robbins JL, Bello A, West C, Bloom BJ.  Dosing 
celecoxib in pediatric patients with juvenile rheumatoid arthritis.  J Clin Pharmacol. 
2012;52:1134- 49.  
Kuehn BM.  FDA: No Codeine After Tonsillectomy for Children. JAMA. 
2013;309(11):1100.  
Lesko SM, Mitchell AA. Renal function after short -term ibuprofen use in infants and 
children. Pediatrics. 1997;100:954- 7. 
   
   40 
Lewis SR, Nicholson A, Cardwell ME, Siviter G, Smith AF. Nonsteroidal anti -inflammatory 
drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database of 
Systematic Reviews 2013;(7): CD003591. 
Li W, Lian YY, Yue WJ, et al.  Experimental study of COX -2 selective and traditional non-
steroidal anti -inflammatory drugs in total hip replacement.  Journal of Internati onal 
Medical Research 2009; 37:472- 78. 
Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP.  Nonsteroidal 
anti-inflammatory drugs are an important cause of acute kidney injury in children. J 
Pediatr. 2013;162:1153- 9. 
Møiniche S, Rømsing J, Dahl JB, et al. Nonsteroidal anti -inflammatory drugs and the risk of 
operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth 
Analg. 2003;96:68- 77. 
Murto K, Lamontagne C, McFaul C, MacCormick J, Ramakko KA, Aglipay M, Rosen D, 
Vaillancourt R.  Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a 
double -blinded randomized controlled study. Can J Anaesth. 2015;62:785 -97. 
Nikanne E, Kokki H, Salo J, Linna TJ.  Celecoxib and ketoprofen for pain management 
during tonsill ectomy: a placebo -controlled clinical trial. Otolaryngol Head Neck Surg. 
2005;132:287- 94. 
Sobel R, Lovell D, Brunner H, et al. Safety of celecoxib and nonselective nonsteroidal anti -
inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. 
Pediatr Rheumatol Online J 2014;12:29. 
Sobol SE, Wetmore RF, Marsh RR, Stow J, Jacobs IN.  Postoperative recovery after 
microdebrider intracapsular or monopolar electrocautery tonsillectomy: a prospective, 
randomized, single -blinded study. Arch Otolaryngol Head Neck Surg. 2006;132:270-
4. 
Stempak D, Gammon J , Klein J, Koren G, Baruchel S.  Single -dose and steady- state 
pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002;72 :490- 7.  
Titchen T, Cranswick N, Beggs S.  Adverse drug rea ctions to nonsteroidal anti -
inflammatory drugs, COX -2 inhibitors and paracetamol in a paediatric hospi[INVESTIGATOR_307].  
British J Clin Pharm 2005; 59:718- 723. 
Van Daele DJ,  Hershberger JM,  Bodeker KL,  Trask DK.  Celecoxib vs. Placebo in 
Tonsillectomy: A Randomized Double Blind Placebo Controlled Trial Comparing 
Analgesia.  Triological Society, Combined Sections Meeting, Miami Beach, [LOCATION_012] 
January 10- 12, 2014. 
Wei JL, Beatty CW, Gustafson RO.  Evaluation of posttonsillectomy hemorrhage and risk 
factors. Otolaryngol  Head Neck Surg. 2000;123:229- 35. 
Wong D, Baker C.  Pain in children: comparison of assessment scales, Pediatric Nursing 
1988; 14:9- 17. 
  
   
   41 
APPENDIX  
 
1. Wong- Baker FACES scale for estimating pain level in children 3 and older  [Wong 
and Baker 1988].  
 
 
 
 
 
2. Ten-point Pain Scale for estimating pain level in older children  (ages 10 and above) . 
 
 
0 
